FDA Rejects Regeneron’s sBLA to Extend EYLEA HD Dosing Interval
Regeneron’s proposal to lengthen EYLEA HD dosing intervals to 24 weeks hits a CRL roadblock. The wait for extended treatment…
A REVOLUTION in Retinal Therapies: From anti-VEGF to TKIs and gene therapy, cutting-edge innovations are changing the landscape of medical retina
Innovations in medical retina are rapidly evolving, and all are aimed at providing safe and optimal care to retina patients….
latest posts
